Literature DB >> 1975922

Treatment of neutropenia associated with dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor.

C L Russo, B E Glader, R J Israel, F Galasso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1975922     DOI： 10.1016/0140-6736(90)92246-e

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  The gastrointestinal manifestations of telomere-mediated disease.

Authors:  Naudia L Jonassaint; Nini Guo; Joseph A Califano; Elizabeth A Montgomery; Mary Armanios
Journal:  Aging Cell       Date:  2013-01-04       Impact factor: 9.304

3.  [Dyskeratosis congenita in a 40-year-old patient].

Authors:  S Benoit; D Kraemer; E-B Bröcker; M Goebeler
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

4.  Treatment of the hematological manifestations of dyskeratosis congenita.

Authors:  C Putterman; R Safadi; J Zlotogora; R Banura; A Eldor
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

5.  Effective stimulation of neutropoiesis with rh G-CSF in dyskeratosis congenita: a case report.

Authors:  L Oehler; E Reiter; J Friedl; E Kabrna; O A Haas; A Rosenkranz; K Lechner; K Geissler
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.